- Home
- CNTB vs MAIA Comparison
CNTB vs MAIA Comparison
Compare CNTB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- MAIA
- Stock Information
- Founded
- CNTB 2012
- MAIA 2018
- Country
- CNTB United States
- MAIA United States
- Employees
- CNTB N/A
- MAIA N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- MAIA Health Care
- Exchange
- CNTB Nasdaq
- MAIA Nasdaq
- Market Cap
- CNTB 44.2M
- MAIA 46.7M
- IPO Year
- CNTB 2021
- MAIA 2022
- Fundamental
- Price
- CNTB $0.98
- MAIA $1.78
- Analyst Decision
- CNTB Strong Buy
- MAIA
- Analyst Count
- CNTB 2
- MAIA 0
- Target Price
- CNTB $7.50
- MAIA N/A
- AVG Volume (30 Days)
- CNTB 92.2K
- MAIA 425.1K
- Earning Date
- CNTB 05-15-2025
- MAIA 08-08-2025
- Dividend Yield
- CNTB N/A
- MAIA N/A
- EPS Growth
- CNTB N/A
- MAIA N/A
- EPS
- CNTB N/A
- MAIA N/A
- Revenue
- CNTB $26,033,000.00
- MAIA N/A
- Revenue This Year
- CNTB N/A
- MAIA N/A
- Revenue Next Year
- CNTB N/A
- MAIA N/A
- P/E Ratio
- CNTB N/A
- MAIA N/A
- Revenue Growth
- CNTB N/A
- MAIA N/A
- 52 Week Low
- CNTB $0.51
- MAIA $1.40
- 52 Week High
- CNTB $1.73
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- CNTB 59.56
- MAIA 50.97
- Support Level
- CNTB $0.91
- MAIA $1.60
- Resistance Level
- CNTB $1.12
- MAIA $1.95
- Average True Range (ATR)
- CNTB 0.08
- MAIA 0.10
- MACD
- CNTB 0.01
- MAIA 0.00
- Stochastic Oscillator
- CNTB 59.26
- MAIA 54.49
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.